CHERISH Events

Established in 2009, the International Network on Health and Hepatitis in Substance Users (INHSU) is a recognized leader in amplifying research and clinical advances in hepatitis C prevention, treatment, and care for people who use drugs. Entering its 11th year, this conference welcomes a global network of practitioners, researchers, community members, and people who use drugs and remains committed to creating equitable access to treatment and health services to address infectious diseases and drug-related harms. Connect with our CHERISH researchers and colleagues attending and view the program outline here.

The 19th International Network on Brief Interventions for Alcohol and Other Drugs (INEBRIA) conference draws an international group of researchers, policymakers, practitioners, and additional stakeholders interested in the potential of brief interventions in health and other settings to reduce the harms produced by alcohol and drug use. This year, the conference revolves around, “Optimizing Brief Interventions for a New Era: From Research to Practice and Policy." Connect with  CHERISH Research Affiliates in person as they present their research at the conference. View the full program here. INEBRIA is organized by CHERISH Research Affiliate Jeremy Bray, and colleagues at UNC Greensboro and the Wake Forest University School of Medicine.

Connect with CHERISH investigators, CHERISH Research Affiliates, Advisory Board members, and pilot grant recipients in person as they present their research at #ARM23.

Connect with CHERISH investigators, CHERISH Research Affiliates, and Advisory Board members in person as they present their research at #CPDD23. The official time zone of the conference is Mountain Time (MDT). View the full program here.

Connect with CHERISH Research Affiliates, Advisory Board members, and pilot grant recipients in person as they present their research at #ASHEcon2023. The official time zone of the conference is Central Daylight Time (CDT).

There has been a substantial increase in the number of jails and prisons offering medications for opioid use disorder (MOUD; namely, methadone, buprenorphine, and naltrexone) in recent years. However, the resources and associated costs required to implement MOUD programs in jails and prisons can vary widely depending on the availability of services and the chosen delivery model.